The in vitro anticoagulant effects of Danaparoid, Fondaparinux, and Lepirudin in children compared to adults

Thrombosis Research

Volumn 122, Issue 5, 2008, Pages 709-714

  Ignjatovic, Vera ^a,b,c   Summerhayes, Robyn ^a,c   Yip, Yan Yan ^b   Monagle, Paul ^a,b  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

Author keywords

Children; Danaparoid; Fondaparinux; Lepirudin

Indexed keywords

DANAPAROID; FONDAPARINUX; LEPIRUDIN; PROTHROMBIN A;

ADULT; AGE; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; CHILD; DRUG EFFECT; ECARIN CLOTTING TIME; ENDOGENOUS THROMBIN POTENTIAL; HEMOSTASIS; HUMAN; HUMAN TISSUE; MEASUREMENT; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PLASMA; PRIORITY JOURNAL; STANDARD;

ADOLESCENT; ADULT; AGE FACTORS; ANTICOAGULANTS; BLOOD COAGULATION; CHILD; CHILD, PRESCHOOL; CHONDROITIN SULFATES; DERMATAN SULFATE; HEPARITIN SULFATE; HIRUDINS; HUMANS; INFANT; PARTIAL THROMBOPLASTIN TIME; POLYSACCHARIDES; RECOMBINANT PROTEINS; WHOLE BLOOD COAGULATION TIME;

EID: 49549086188     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.02.001     Document Type: Article

References (15)

1. Subramaniam B., and Park K.W. Direct Thrombin Inhibitors. Int Anesthesiol Clin 43 2 (2005) 39-53
2. Gurm H.S., and Bhatt D.L. Thrombin, an ideal target for pharmacological inhibition: A review of direct thrombin inhibitors. Am Heart J 149 (2005) S43-S53
3. Bidlingmaier C., Magnani H., Girisch M., and Kurnik K. Safety and efficacy of Danaparoid (Orgaran) for use in children. Acta Haematol 115 3-4 (2006) 237-247
4. Martchenke J., and Boshkov L. Heparin-induced thrombocytopenia in neonates. J Neon Nurs 24 5 (2005) 33-37
5. Ranze O., Ranze P., Magnani H.N., and Greinacher A. Heparin-induced thrombocytopenia in paediatric patients: a review of the literature and a new case treated with danaparoid sodium. Eur J Pediatr 158 Suppl 3 (1999) S130-S133
6. Risch L., Fischer J.E., Herklotz R., and Huber A. Heparin-induced thrombocytopenia in paediatrics: clinical characteristics, therapy and outcomes. Intensive Care Med 30 8 (2004) 1615-1624
7. Saxon B.R., Black M.D., Edgell D., Noel D., and Leaker M.T. Pediatric heparin-induced thrombocytopenia: management with Danaparoid (Oragaran). Ann Thorac Surg 68 3 (1999) 1076-1078
8. Zohrer' B., Zenz W., Rettenbacher A., Covi P., Kurnik K., and Kroll H. Danaparoid sodium (Orgaran) in four children with heparin-induced thrombocytopenia type II. Acta Paedagog 90 7 (2001) 765-771
9. Baier K., Cvirn G., Fritsch P., Kostenberger M., Gallistl S., Leschnik B., et al. Higher concentrations of Heparin and Hirudin are required to inhibit thrombin generation in Tissue Factor-Activated cord plasma than in adult plasma. Paediatr Respir 57 5 (2005) 685-689
10. Andrew M., Paes B., Milner R., Jonston M., Mitchell L., Tollefsen D., et al. Development of the human coagulation system in the full-term infant. Blood 70 1 (1987) 165-172
11. Andrew M., Paes B., Milner R., Jonston M., Mitchell L., Tollefsen D., et al. Development of the Human coagulation system in the healthy premature infant. Blood 72 5 (1988) 1651-1657
12. Andrew M., Vegh P., Johnston M., Bowker J., Ofosu F., Mitchell L., et al. Maturation of the hemostatic system during childhood. Blood 80 8 (1992) 1998-2005
13. Ignjatovic V., Furmedge J., Newall F., Chan A., Berry L., Fong C., et al. Age-related differences in Heparin response. Thromb Res 118 6 (2006) 741-745
14. Ignjatovic V., Summerhayes R., Gan A., Than J., Chan A., Cochrane A., et al. Monitoring Unfractionated Heparin (UFH) therapy: which Anti Factor Xa assay is appropriate?. Thromb Res 120 (2006) 347-351
15. Fritsma G.A. Direct Thrombin Inhibitors. Clin Lab Sci 17 2 (2004) 118-123